Cel
Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families.
Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life. RESSTORE European multicentre randomised phase IIb will explore, for the first time, the efficacy (functional recovery) and safety of intravenous infusion of allogenic adipose tissue derived mesenchymal stem cells (ADMSCs) in 400 stroke patients. Therapeutic effects of ADMSCs will be assessed and monitored in patients using clinical rating scales, multimodal MRI and novel blood biomarkers. Additionally, the societal value and cost-effectiveness of ADMSCs-based regenerative therapy will be evaluated through health economics and predictive in silico simulations. Complementary ancillary animal studies will support the clinical trial by defining i) if the treatment response can be further enhanced by intensive rehabilitation, ii) the contribution of co-morbidities and iii) the mechanism(s) underlying the therapeutic effect.
The European regenerative therapy capacities (France, Spain, Finland, United Kingdom and Czech Republic), developed in RESSTORE will cover the full value chain in the field (large scale GMP cell production, clinical testing, biomarkers discovery, understanding of the restoring mechanisms, modelling, biobanking, economic studies, exploitation and communication plan). RESSTORE will thus surely contribute, together with the workforce trained in the context of the programme, to improve its public and private (SME) competitiveness and increase the attractiveness of Europe as a reference location to develop and clinically assess new innovative therapeutic options for brain diseases.
Dziedzina nauki
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health sciencesclinical medicinephysiotherapy
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicineneurologystroke
- social scienceseconomics and businesseconomicshealth economics
Słowa kluczowe
Program(-y)
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSzczegółowe działanie
H2020-PHC-2015-single-stage_RTD
System finansowania
RIA - Research and Innovation actionKoordynator
38058 Grenoble
Francja
Zobacz na mapie
Uczestnicy (28)
28046 MADRID
Zobacz na mapie
38700 La Tronche
Zobacz na mapie
602 00 Brno
Zobacz na mapie
41071 Sevilla
Zobacz na mapie
G12 8QQ Glasgow
Zobacz na mapie
70211 KUOPIO
Zobacz na mapie
93210 La Plaine Saint Denis
Zobacz na mapie
33100 Tampere
Zobacz na mapie
48160 Derio Bizkaia
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
70700 Kuopio
Zobacz na mapie
75654 Paris
Zobacz na mapie
08035 Barcelona
Zobacz na mapie
69002 Lyon
Zobacz na mapie
95021 Cergy Pontoise Cedex
Zobacz na mapie
69009 Lyon
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
69003 Lyon
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
25030 BESANCON CEDEX
Zobacz na mapie
75012 Paris
Zobacz na mapie
31052 Toulouse Cedex 3
Zobacz na mapie
33404 Talence
Zobacz na mapie
14033 Caen Cedex 5
Zobacz na mapie
42002 Soria
Zobacz na mapie
08041 Barcelona
Zobacz na mapie
45007 Toledo
Zobacz na mapie
15703 Santiago De Compostela
Zobacz na mapie
17190 Girona
Zobacz na mapie
33521 Tampere
Zobacz na mapie
75014 Paris
Zobacz na mapie